The diagnostic value of interleukin 6 as a biomarker for gastric cancer
A meta-analysis and systematic review
Xiaozi Wang, MDa, Jie Li, PhDb, Wenjing Liu, MDa, Xianghong Zhang, PhDa, Liying Xue, PhDa,∗

Abstract

Background: Gastric cancer is one of the most common cancers and a main cause of global cancer death. The expression of interleukin 6 is associated with the risk of gastric cancer. But the diagnostic accuracy of interleukin 6 remains unclear. This study was designed to assess the diagnostic performance of interleukin 6 in gastric cancer diagnosis.

Methods: The related data was obtained from Oncomine and studied using bioinformatics analysis. The PubMed, Embase, Cochrane Library, Web of science databases were searched for related studies published from inception to July 14, 2020. Measuring tools of diagnostic performance including sensitivity, specificity, and diagnostic odds ratio were pooled using bivariate mixed-effects meta-analysis model. The summery receiver operator characteristic curves were plotted.

Results: The result from Oncomine showed that the expression of interleukin 6 in gastric cancer (GC) patients was higher than the normal groups (P < .05). Furthermore, a total of 4 eligible articles were enrolled, containing 390 cases and 404 controls. The diagnostic results were as follows: a sensitivity of 0.80 (95% confidence interval [CI] 0.57–0.92), a specificity of 0.86 (95% CI 0.74–0.93), a positive likelihood ratio of 5.76 (95% CI 3.49–9.49), a negative likelihood ratio of 0.23 (95% CI 0.11–0.51) and a diagnostic odds ratio of 24.58 (95% CI 14.14–42.73). The summary area under the receiver operating characteristic curves was 0.90 (95% CI 0.87–0.93).

Conclusion: Higher interleukin 6 expression was detected in GC patients, and interleukin 6 could be a helpful indicator of diagnosis of gastric cancer. Further large-scale prospective studies are required for identifying the diagnostic value of interleukin 6 in gastric cancer.

Abbreviations: AUC = area under the curve, CA = carbohydrate antigen, CI = confidence interval, DOR = diagnostic odds ratio, FN = false negatives, FP = false positive, GC = gastric cancer, IL-6 = interleukin 6, NLR = negative likelihood ratio, PLR = positive likelihood ratio, TN = true negative, TP = true positives.

Keywords: biomarker, gastric cancer, interleukin 6

1. Introduction

Gastric cancer (GC) is one of the most common cancers and a main cause of global cancer deaths. In 2018, it was estimated that there were 1,033,701 new GC cases and 782,685 deaths caused by GC worldwide. The most crucial to reduce GC mortality are accurate diagnosis and tumor treatment at early stage. Until now, there were several detection tools of GC, such as endoscopy, biopsy and serum biomarkers. However, the endoscopy and biopsy are uncomfortable and invasive for patients. Meanwhile, the routine clinical detection of serum biomarkers for example carbohydrate antigen (CA) 19–9 and CA724 are low sensitivity and specificity in the diagnosis of GC. Therefore, it is a great need for new reliable noninvasive biomarkers for the detection of GC.

Interleukin 6 (IL-6), involved in T-cell, natural killer cells and macrophages differentiation, is one of the important cytokines in the tumor microenvironment. It has been reported that IL-6 plays important roles in the development of many human cancers, such as primary lung adenocarcinomas and breast cancer. Numerous studies have shown that IL-6 induces the proliferation of cancer cells, and then contributes to tumor invasion and progression. GC patients with stage IV showed significant
higher level of serum IL-6 than cases with stage II and III, indicating
that IL-6 might be related with the TNM stage, lymph node
metastasis and the invasion depth in GC.[14–15] Meanwhile, the
research carried out by Lin et al.[16] demonstrated that IL-6 could
promote invasion of GC cells through activating the c-Src/RhoA/
ROCK signal pathway. Accordingly, IL-6 must be involved in the
carcinogenesis of GC.[17]
Recent studies showed that high level of serum IL-6 was
associated with the cancer cachexia in patients with prostate cancer,
and correlated with poor survival of metastatic breast cancer
patients.[18,19] It was reported that the elevated serum IL-6 level was
associated with distant metastasis of esophageal squamous cell
carcinoma (ESCC). Meanwhile, the positive IL-6 expression was
significantly associated with shorter survival of patients with ESCC,
and its inhibitor could decrease the invasion of esophageal cancer
cells in vitro and in vivo.[20] Compared to the healthy subjects, levels
of serum IL-4, C-reactive protein (CRP) and IL-6 were higher in
hepatocellular carcinoma patients, and elevated serum IL-6 level
was considered to be a risk indicator for hepatocellular carcinoma
using with multivariate analysis.[21,22] IL-6, therefore, has been
regarded as a potential prognostic factor for various cancers.[26–28]
To date, several studies showed that higher level of serum IL-6 not
only was associated with an increased risk of GC,[23–25] but also was
related with invasion depth.[15] Thus, high serum IL-6 level in
GC patients might be an independent predictor of poor progno-
sis.[29] Previous researches have evidenced that IL-6 can serve as a
diagnostic biomarker in many human cancers.[29,30] However,
whether IL-6 is used as a good biomarker for GC diagnosis is not
clear.
Therefore, the expression of IL-6 in GC was analyzed by
bioinformatics. The meta-analysis was conducted systematically,
and the related literatures were reviewed in this study.

2. Methods

2.1. Bioinformatics

The expression profiles of IL-6 in GC patients and the controls
were downloaded from the Oncomine database (https://www.
oncomine.org), and then the SPSS16.0 was used to analyze the
data.

2.2. Search strategy and selection criteria

We systematically and comprehensively searched PubMed,
Embase, the Cochrane Library and Web of science for studies
Published before July 14, 2020. The terms used for literature
retrieval were (“Interleukin 6” or “IL6” or “IL6R”) and
(“Stomach Neoplasms” or “Gastric Neoplasms” or “Gastric
Neoplasm” or “Cancer of Stomach” or “Stomach Cancers” or
“Gastric Cancer” or “Gastric adenocarcinoma”) and (“diagno-
sis” or “sensitivity and specificity” or “ROC curve”). The titles
and abstracts of the articles were checked, and the relevant full
texts were scanned by 2 reviewers. The references of each primary
identified study and review were also examined. This study was
reviewed and approved by The Institutional Review Board of
Hebei Medical University.

2.3. Study selection

In this meta-analysis, eligible studies met the following criteria:

1. the GC patients were confirmed by pathological examination;
2. interleukin 6 concentration was detected before any treatment;
3. the study investigated the correlation between the expression
   of interleukin 6 and GC;
4. the study provided available data to extract or calculate the
   2*2 table consisting of true positives (TP), false positive (FP),
   false negatives (FN), and true negative (TN).

The exclusion criteria were:

1. duplicate publications;
2. literatures irrelevant to the diagnostic values of interleukin 6
   for GC;
3. case reports, conference abstracts, reviews, editorials, meta-
   analysis, comments and letters;
4. studies in vitro, on animal models and human cell lines;
5. insufficient data.

2.4. Data extraction

Two researchers independently extracted data. The following
items from each study were recorded: name of first author,
publishation year, country, sample type, detection method, sample
size (cases/controls), cut-off value, sensitivity, specificity, TP, FP,
FN, TN values and QUADAS-2 score.

2.5. Quality assessment

The Quality Assessment of Diagnostic Accuracy Studies
(QUADAS-2)[31] list in Rev Man 5.3 software (RevMan; the
Cochrane Collaboration, Oxford, UK) was used to evaluate the
quality of the diagnostic test studies. The scale contained 4
domains: Patient Selection, Index Test, Reference Standard, and
Flow and Timing. All domains were assessed in terms of risk of
bias, but the applicability concern applied to the first 3 domains.
The answer of each question was determined by “yes” “no” or
“unclear,” and the risk of bias and concern for applicability were
estimated as “high,” “low” or “unclear.”

2.6. Statistical analysis

The specificity and sensitivity parameters were extracted and the
TP, FP, FN, TN were extracted or calculated. Statistical analyses
were conducted using the Stata/SE 15.1 software (StataCorp
LLC, College Station, TX, USA). The bivariate mixed-effects
meta-analysis model was used to evaluate the pooled sensitivity,
specificity, diagnostic odds ratio (DOR), positive likelihood ratio
(PLR), negative likelihood ratio (NLR), and the area under
the summery receiver operating characteristic curves. The area under
the summary ROC curve has been considered as a global measure
of test performance. The AUSROC values of 0.5–0.7, 0.7–0.9,
0.9–1.0 indicated low, moderate, or high accuracy, respective-
ly.[32] Inconsistency index and Cochran Q tests were used to
assess the heterogeneity.[33,34] The diagnostic threshold effects
were analyzed by Spearman’s correlation coefficient and ROC
plane analysis. Fagan plot was performed to reveal the
relationship between the prior probability specified by user,
the likelihood ratio, and the posterior test probability.[35]

3. Results

3.1. Expression levels of interleukin 6 in patients with
gastric cancer

The Chen’s, Cho’s, DErrico’s, and TCGA’s Statistics from
Oncomine database were used to perform bioinformatics analysis
The data of Chen set revealed that there were no significant differences in IL-6 at mRNA level between the GC and normal group (P > .05) (Fig. 1A). However, the data of Cho and DErrico datasets analysis showed that the mRNA expression levels of IL-6 were significantly higher in the GC than the normal group (P < .05) (Fig. 1B, C). The higher IL-6 DNA level was also detected in GC patients based on the TCGA dataset (P < .05) (Fig. 1D).

3.2. Study selection and characteristics of eligible studies

A total of 803 articles were searched. Firstly, we removed the duplicated articles (n = 90). After a scan of titles and abstracts, 169 reviews, 8 meta-analysis, 17 comments, 37 case reports, 14 editorials, 35 conference abstracts and 408 irrelevant articles were removed. After a more detailed evaluation, 21 studies were excluded for not relevant diagnosis and insufficient data. Finally, 4 studies[23,29,36,37] were eligible for the meta-analysis, which included 390 cases and 404 controls. The process of literature selection is presented in Figure 2. All of the samples were from serum, and more detailed characteristics of included studies were showed in Table 1.

3.3. Quality assessment

The quality of the included studies was evaluated by QUADAS-2. Overall, 2 studies had a score of 4,[23,29] and 2 studies had a score of 6[36,37] (Fig. 3).

3.4. Data analysis

The sensitivity and specificity of IL-6 in diagnosing GC are shown in the corresponding forest plots (Fig. 4A). The indexes from 4 included studies were as follows: sensitivity 0.80 (95% confidence interval [CI], 0.57–0.92), specificity 0.86 (95% CI, 0.74–0.93), PLR 5.76 (95% CI, 3.49–9.49), NLR 0.23 (95% CI, 0.11–0.51) (Fig. 6) and DOR 24.58 (95% CI, 14.14–42.73) (Fig. 4C). The area under the curve (AUC) of IL-6 was 0.90 (95% CI, 0.87–0.93), and the summary receiver operator characteristic curve of the included studies was shown in Figure 4B. Given a pretest probability of 50%, using IL-6 to diagnose GC improved the post-test probability of positive result to 85%, and reduced post-test probability of the negative result to 19% with a NLR of 0.23 (Fig. 4D).

3.5. Threshold effect and heterogeneity

In this analysis, the ROC plane showed a non-typical shoulder arm appearance, indicating that there might be no threshold effect (Fig. 5). Furthermore, the calculated Spearman’s correlation coefficient was 0.2 (P = .8), suggesting that there was no threshold effect. The overall inconsistency index for bivariate model was 98% (95% CI 96–99%), reflecting that heterogeneity existed among the studies. The subgroup, meta-regression and sensitivity analyses could not be conducted to identify the source of the heterogeneity, because that only 4 studies were included in this meta-analysis.
4. Discussion

GC is responsible for one of the highest cancer-related mortality. The key to reduce the mortality is accurate diagnosis tools. The universal screening methods are invasion and uncomfortable, and the investigated biomarkers such as the carcinoembryonic antigen, CA 19-9 and CA724 are low sensitivity or specificity for the diagnosis of GC. Therefore, it is necessary to explore the reliable noninvasive biomarkers to detect GC. Previous studies showed that IL-6 was elevated in multiple human cancers, but it was challenging to regard the IL-6 as an independent deterministic diagnostic biomarker for a single type of cancer. In GC, IL-6 was reported to play important roles in the tumorigenesis owing to the different IL-6 expression levels observed between GC patients and healthy controls. However, the diagnostic accuracy of IL-6 for GC remains unclear.

Recently, a meta-analysis to assess the diagnosis value of serum IL-6 in colorectal cancer suggested that IL-6 could be used to screening out the colorectal cancer patients from healthy subjects. It has been evidenced that the IL-6 levels were elevated significantly in advanced gastrointestinal cancer patients. One previous research on IL-17 and IL-23 showed that patients with gastric neoplasms have significantly lower IL-23 levels with comparison to healthy individuals, while IL-17 levels existed no significant difference between GC and healthy individuals. Although the systemic levels of examined interleukins had no associations with tumor TNM staging,

Table 1

| Author       | Year | Country | Sample type | Method | Cases/controls | Cut-off (pg/mL) | TP | FP | FN | TN | Sensitivity % | Specificity % | QUADAS-2 score |
|--------------|------|---------|-------------|--------|----------------|-----------------|----|----|----|----|---------------|---------------|----------------|
| Ashizawa T   | 2005 | Japan   | Serum       | CLEIA  | 33/15          | 1.97            | 27 | 5  | 6  | 10 | 81.8          | 66.7          | 4              |
| Lukaszewicz-Zajac M | 2011 | Poland  | Serum       | ELISA  | 92/70          | 2.46            | 78 | 15 | 14 | 55 | 85            | 78.86         | 6              |
| Sánchez-Zauco N | 2017 | Mexico  | Serum       | xMAP   | 89/115         | 3.25            | 35 | 4  | 54 | 111 | 39           | 97             | 4              |
| Li J         | 2018 | China   | Serum       | Luminex 200 | 176/204      | 20.31           | 162 | 43 | 14 | 161 | 92.05         | 78.92         | 6              |

FN = false negative, FP = false positive, QUADAS-2 = quality assessment of diagnostic accuracy studies 2, TP = true positive.
IL-17 levels interestingly differed between patients with early and advanced gastric carcinoma. The other comprehensive study for several interleukins including IL-1, IL-6, IL-8, IL-10, and IL-12 demonstrated that patients with GC had significant higher IL-6 level, and lower IL-8 and IL-10 level, compared with the controls. Meanwhile, IL-6/IL-8 and IL-6/IL-10 ratios were also higher in GC patients, indicating that the ratios of interleukins might hold diagnostic potential in confirming or excluding GC (with a sensitivity and specificity of approximately 54%–72%). However, there were inconsistent results between different studies. For example, 1 study found that IL-6 protein expression was elevated in GC tumor tissue, and was related to the TNM stage using western blot and immunohistochemistry. However, high-sensitivity ELISA analysis revealed that serum IL-6 levels and the IL-6/IL-8, IL-6/IL-10 ratios were not significantly associated with the TNM stage of GC. Due to these inconsistent results, whether the IL levels or IL ratios were enough sensitive or specific as an independent deterministic marker for GC diagnosis remains unclear. In this study, we analyzed the expression levels of IL-6 in GC using bioinformatics analysis based on the Oncomine. The data from Chen dataset showed that there were no statistically significant differences in IL-6 at mRNA level between the GC and normal group. However, Cho and DErrico datasets analysis showed that the mRNA expression levels of IL-6 were higher in GC. And the data from TCGA dataset also revealed that the expression of IL-6 at DNA level was significantly higher in GC patients. Therefore, IL-6 was speculated to be a potential biomarker for GC diagnosis, consistent with the previous research.

To further clarify the role of IL-6 in GC diagnosis, we searched for related studies published from inception to July 14, 2020 in PubMed, Embase, Cochrane Library, Web of science databases and performed the meta-analysis. Four articles on utilizing serum-based IL-6 diagnosing GC, including 390 patients and 404 controls were carefully reviewed. We found that compared with the healthy control group, serum IL-6 level was significantly upregulated in GC patients, resemble with our analysis based on Oncomine. Summery receiver operator characteristic was used to judge the test performance, and AUC was used to assess the discriminating ability. An AUC of IL-6 is 0.90 (95% CI, 0.87–0.93), with a sensitivity 0.80 (95% CI, 0.57–0.92) and a specificity 0.86 (95% CI, 0.74–0.93). These results demonstrate that IL-6 has a moderate diagnostic value. The pooled DOR is 24.58 (95%CI 14.14–42.73), indicating that the use of IL-6 for GC diagnosis is credible. The PLR of 5.76 (95% CI, 3.49–9.49) and the NLR of 0.23 (95% CI, 0.11–0.51) imply that patients with GC had 5.8 times higher probability of being IL-6 positive, compared with the healthy adults. The present study showed that the specificity, the sensitivity and the accuracy are as good as the other markers previous reported, such as carcinoembryonic antigen and (CA) 19–9, and indicated that IL-6 may be a reliable biomarker in GC detection and diagnosis.
there is high heterogeneity among the selected studies in the present meta-analysis because of the confounding factors, in which threshold effect must be the first considerable factor. We further analyzed the threshold effect using the Spearman’s correlation test, and the Spearman’s correlation coefficient was 0.2 \( (P=.8) \). It suggested that threshold effect is not the main source of heterogeneity in our analysis. However, we failed to explore the sources of heterogeneity by meta-regression analysis, sensitivity analysis and subgroup analysis, because only 4 articles were enrolled in our meta-analysis.

It has been reported that IL-6, in the tumor microenvironment, is produced by tumor-infiltrating immune cells, stromal cells, and the tumor cells themselves.\[^{49}\] IL-6 could not only stimulate cancer cells growth and activate the Rho protein, which is associated with invasion and cell-cell adhesion in cancers.\[^{16,50}\] but also promote angiogenesis and suppress apoptosis through elevating the levels of vascular endothelial growth factor (VEGF) in basal cell carcinoma and cervical carcinoma.\[^{51,52}\] In vitro experiments, IL-6/STAT3 signaling could induce GC cell growth through regulating its downstream target IncRNA GACAT3 in GC cell lines (SGC-7901

---

**Figure 4.** Forest plots of the pooled sensitivity and specificity of the IL-6 detection for GC (A). Pooled summary receiver operating characteristic curve of IL-6 for the diagnosis of GC in the studies included. Also shows 95% confidence contour and 95% prediction contour (B). Forest plots of the pooled diagnostic odds ratio for IL-6 in the diagnosis of GC (C). Fagan nomogram for evaluating the post-test probabilities (D).

**Figure 5.** ROC space for assessing the threshold effect of IL-6 for GC.
and HGC-27 cells.\[53\] Additionally, the inhibitors of JAK/STAT3 (AG490) could reduce cell proliferation and invasion promoted by exogenous IL-6.\[10\] Thus, these data suggested that IL-6 appears to be a promising target for treatment of GC.

There were a few limitations in this study. First, the number of eligible studies and the included participants were small. Second, the sensitivity analysis, meta-regression and subgroup analysis were not performed to interpret heterogeneity. To fetch up these shortages, we added bioinformatics analysis for IL-6 at mRNA and DNA level based on Oncomine datasets. In summary, our study showed that IL-6 expression was significantly higher in GC samples and patients’ serum, and then revealed that IL-6 must be a non-invasive, inexpensive and a helpful marker for diagnosis of GC. In the future, the serum levels of IL-6, combined with other biomarkers, are required to be detected in a large population in order to improve the diagnostic accuracy and organ specificity.

Author contributions
Conceptualization: Jie Li, Xianghong Zhang, Liying Xue.
Data curation: Xiaozi Wang, Jie Li, Wenjing Liu.
Formal analysis: Xiaozi Wang, Jie Li, Wenjing Liu, Liying Xue.
Funding acquisition: Liying Xue.
Methodology: Jie Li.
Software: Wenjing Liu, Liying Xue.
Supervision: Xianghong Zhang, Liying Xue.
Writing – original draft: Xiaozi Wang.
Writing – review & editing: Jie Li, Xianghong Zhang, Liying Xue.

References
[1] Fitzmaurice C, Abate D, Abbasi N, et al. Global Burden of Disease Cancer CollaborationGlobal, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol 2019; 5:1749–68.
[2] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68:394–424.
[3] Emoto S, Ishigami H, Yamashita H, Yamaguchi H, Kaisaki S, Kitayama J. Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination. Gastric Cancer 2012;15:154–61.
[4] Kanda M, Fuji T, Takami H, et al. The combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients. Surg Today 2014;44:1692–701.
[5] Jeannin P, Duluc D, Delneste Y. IL-6 and leukemia-inhibitory factor are involved in the generation of tumor-associated macrophage: regulation by IFN-γ. Immunotherapy 2011;3(4 Suppl):23–6.
[6] Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993;54:1–78.
[7] Kim HW, Lee JC, Paik KH, Kang J, Kim J, Hwang JH. Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern. Medicine (Baltimore) 2017;96:e5926.
[8] Gao SP, Mark KG, Leslie K, et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007;117:3846–56.
[9] Leslie K, Gao SP, Berishaj M, et al. Differential interleukin-6/Stat3 signaling as a function of cellular context mediates Ras-induced transformation. Breast Cancer Res 2010;12:R80.
[10] Zhao G, Zhu G, Huang Y, et al. IL-6 mediates the signal pathway of JAK-STAT3-VEGF-C, promoting growth, invasion and lymph angiogenesis in gastric cancer. Oncol Rep 2016;35:1787–95.
[11] Bharti R, Dey G, Das AK, Mandal M. Differential expression of IL-6/IL-6R and MAO-A regulates invasion/angiogenesis in breast cancer. Br J Cancer 2018;118:1442–52.
[12] Liu W, Wang H, Bai F, et al. IL-6 promotes metastasis of non-small-cell lung cancer by up-regulating TIM-4 via NF-κB. Cell Prolif 2020;53:e12776.
[13] Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012;38:904–10.
[14] Ilhan N, Ilhan N, Ilhan Y, Akbulut H, Kucukcu M. C-reactive protein, procalcitonin, interleukin-6, vascular endothelial growth factor and...
oxidative metabolites in diagnosis of infection and staging in patients with gastric cancer. World J Gastroenterol 2004;10:1115–20.

[15] Kim DK, Oh SY, Kwon HC, et al. Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer 2009;9:135.

[16] Lin MT, Lin BR, Chang CC, et al. IL-6 induces AGS gastric cancer cell invasion via activation of the c-Src/RhoA/ROCK signaling pathway. Int J Cancer 2007;120:2600–8.

[17] Ito R, Yutai W, Kuniyasu H, Yokozaki H, Tahara E. Expression of interleukin-6 and its effect on the cancer growth of gastric carcinoma cell lines. Jpn J Cancer Res 1997;88:953–8.

[18] Kuroda K, Nakashima J, Kanao K, et al. Interleukin 6 is associated with inflammation in patients with prostate cancer. Urology 2007;69:113–7.

[19] Salgado R, Junius S, Benoy I, et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 2003;103:642–6.

[20] Chen MF, Chen PT, Lu MS, Lin PY, Chen WC, Lee KD. IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus. Mol Cancer 2013;12:26.

[21] Ohishi W, Cologne JB, Fujiwara S, et al. Serum interleukin-6 associated with hepatocellular carcinoma risk: a nested case-control study. Int J Cancer 2014;134:154–63.

[22] Jiang JW, Ob BS, Kwon JH, et al. Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma. Cytokine 2012;60:686–93.

[23] Sánchez-Zauco N, Torres J, Gómez A, et al. Circulating blood levels of IL-6, IFN-γ, and IL-10 as potential diagnostic biomarkers in gastric cancer: a controlled study. BMC Cancer 2017;17:384.

[24] Wong HL, Rabkin CS, Shu XO, et al. Systemic cytokine levels and subsequent risk of gastric cancer in Chinese Women. Cancer Sci 2011;102:1911–5.

[25] Szczepanik AM, Scislo L, Scully T, et al. IL-6 serum levels predict postoperative morbidity in gastric cancer patients. Gastric Cancer 2011;14:266–73.

[26] Song Z, Lin Y, Ye X, et al. Expression of IL-1α and IL-6 is associated with progression and prognosis of human cervical cancer. Med Sci Monit 2016;22:4475–81.

[27] Guðbrandsdóttir G, Aarstad HH, Bostad L, et al. Serum levels of the IL-6 family of cytokines predict prognosis in renal cell carcinoma (RCC). Cancer Immuno Therapeut 2020;10.1007/s00262-020-02655-z.

[28] Zhan X, Gao H, Sun W. Correlations of IL-6, IL-8, IL-10, IL-17 and TNF-α with the pathological stage and prognosis of glioma patients. Minerva Med 2020;111:192–5.

[29] Ashizawa T, Okada R, Suzuki Y, et al. Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer 2005;8:124–31.

[30] Groblewska M, Mroczko B, Wereszczyńska-Siemiatkowska U, et al. Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients. Clin Chem Lab Med 2015;53:289–96.

[31] Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2 Group: QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:329–36.

[32] Swets JA. Measuring the accuracy of diagnostic systems. Science 1988;240:1285–93.

[33] Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60.

[34] Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–58.

[35] Fagan TJ. Letter: nomogram for bayes theorem. N Engl J Med 1975;293:257.

[36] Lukaszewicz-Zajać M, Mroczko B, Gryko M, Kędra B, Szmitkowski M. Comparison between clinical significance of serum proinflammatory proteins (IL-6 and CRP) and classic tumor markers (CEA and CA 19-9) in gastric cancer. Clin Exp Med 2011;11:89–96.

[37] Li J, Xu L, Run ZC, et al. Multiple cytokine profiling in serum for early detection of gastric cancer. World J Gastroenterol 2018;24:2269–78.

[38] Chen XZ, Zhang WK, Yang K, et al. Correlation between serum CA724 and gastric cancer: multiple analyses based on Chinese population. Mol Biol Rep 2012;39:9031–9.

[39] Madej-Michniewicz A, Budkowska M, Salata D, et al. Evaluation of selected interleukins in patients with different gastric neoplasms: a preliminary report. Sci Rep 2015;5:14382.

[40] Vainer N, Dehrendorf C, Johansen JS. Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer. Oncotarget 2018;9:29820–41.

[41] Ahn HS, Shin YS, Park PJ, et al. Serum biomarker panels for the diagnosis of gastric adenocarcinoma. Br J Cancer 2012;106:733–9.

[42] Xu J, Ye Y, Zhang H, et al. Diagnostic and prognostic value of serum interleukin-6 in colorectal cancer. Medicine (Baltimore) 2016;95:e2502.

[43] Tong Q, Wang XL, Li SB, et al. Combined detection of IL-6 and IL-8 is beneficial to the diagnosis of early stage esophageal squamous cell cancer: a preliminary study based on the screening of serum markers using protein chips. Onco Targets Ther 2018;11:3777–87.

[44] Błogowski W, Madej-Michniewicz A, Marczuk N, et al. Interleukins 17 and 23 in patients with gastric neoplasms. Sci Rep 2016;6:37451.

[45] Wang Z, Xi X, Xu A, et al. Activation of STAT3 in human gastric cancer cells via interleukin (IL)-6-type cytokine signaling correlates with clinical implications. PLoS One 2013;8:e75788.

[46] Rosman AS, Korsten MA. Application of summary receiver operating characteristics (sROC) analysis to diagnostic clinical testing. Adv Med Sci 2007;52:76–82.

[47] Walter SD. Properties of the summary receiver operating characteristic (sROC) curve for diagnostic test data. Stat Med 2002;21:1237–56.

[48] Liang Y, Wang W, Fang C, et al. Clinical significance and diagnostic value of serum CEA, CA 19-9 and CA 72-4 in patients with gastric cancer. Oncotarget 2016;7:49565–73.

[49] Kumari N, Dwarkanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol 2016;37:11533–72.

[50] Lee SO, Yang X, Duan S, et al. IL-6 promotes growth and epithelial-mesenchymal transition of CD133+ cells of non-small cell lung cancer. Oncotarget 2016;7:6626–38.

[51] Jee SH, Shen SC, Chiu HC, Tsai WL, Kuo ML. Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency. Oncogene 2001;20:198–208.

[52] Wei LH, Kuo ML, Chen CA, et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 2003;22:1517–27.

[53] Shen W, Yuan Y, Zhao M, et al. Novel long non-coding RNA GACAT3 promotes gastric cancer cell proliferation through the IL-6/STAT3 signaling pathway. Tumour Biol 2016;37:14895–902.